About Inipharm
Inipharm is a company based in Seattle (United States) founded in 2018 by Brian Farmer and Michael Gallatin.. Inipharm has raised $35 million across 1 funding round from investors including Frazier Healthcare Partners, Jubilant Biosys and 5AM Ventures. Inipharm offers products and services including INI-822. Inipharm operates in a competitive market with competitors including Aclaris Therapeutics, NGM Biopharmaceuticals, Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences, among others.
- Headquarter Seattle, United States
- Founders Brian Farmer, Michael Gallatin
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$35 M (USD)
in 1 rounds
-
Latest Funding Round
$35 M (USD), Series A
Nov 11, 2020
-
Investors
Frazier Healthcare Partners
& 3 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Inipharm
Inipharm offers a comprehensive portfolio of products and services, including INI-822. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Inhibits HSD17B13 to reduce fibrotic markers in liver diseases.
Unlock access to complete
Leadership Team
12 people
Scientific Team
7 people
Operations Team
1 people
Unlock access to complete
Funding Insights of Inipharm
Inipharm has successfully raised a total of $35M through 1 strategic funding round. The most recent funding activity was a Series A round of $35 million completed in November 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $35.0M
-
First Round
First Round
(11 Nov 2020)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2020 | Amount | Series A - Inipharm | Valuation | 5AM Ventures , Wu Capital |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Inipharm
Inipharm has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Frazier Healthcare Partners, Jubilant Biosys and 5AM Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund backed incubator focused on the healthcare startups
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Healthcare sector private equity investments are managed by the firm.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Inipharm
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Inipharm
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Inipharm Comparisons
Competitors of Inipharm
Inipharm operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aclaris Therapeutics, NGM Biopharmaceuticals, Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel dermatologic therapies are developed for skin conditions.
|
|
| domain | founded_year | HQ Location |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies to treat cancer and autoimmune disorders
|
|
| domain | founded_year | HQ Location |
GPCR drug discovery platform is developed for multiple diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Inipharm
Frequently Asked Questions about Inipharm
When was Inipharm founded?
Inipharm was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Where is Inipharm located?
Inipharm is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Who is the current CEO of Inipharm?
Brian Farmer is the current CEO of Inipharm. They have also founded this company.
Is Inipharm a funded company?
Inipharm is a funded company, having raised a total of $35M across 1 funding round to date. The company's 1st funding round was a Series A of $35M, raised on Nov 11, 2020.
What does Inipharm do?
Inipharm was founded in 2018 in Seattle, United States, within the biotechnology sector. Focus is placed on creating targeted therapies for severe liver conditions. A small-molecule product, HSD17B13, has been developed to address liver damage, including reductions in inflammation and fibrosis. Operations center on advancing these treatments through research and development in the pharmaceutical field.
Who are the top competitors of Inipharm?
Inipharm's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences.
What products or services does Inipharm offer?
Inipharm offers INI-822.
Who are Inipharm's investors?
Inipharm has 4 investors. Key investors include Frazier Healthcare Partners, Jubilant Biosys, 5AM Ventures, and Wu Capital.